MEDI 120-Development of novel and potent inhibitors of JAK2: Structure activity relationship studies for optimiziation of JAK2 potency while minimizing JAK3 activity

被引：0
|
作者：
Reddy, Venkata J. [1 ]
Mereddy, Venkatram R. [1 ]
机构：
[1] Univ Minnesota, Dept Chem & Biochem, Duluth, MN 55812 USA
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2007年 / 233卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
103-MEDI
引用
收藏
页码：895 / 895
页数：1
相关论文
共 50 条
  • [1] Development of novel and potent inhibitors of JAK2: Structure activity relationship studies for optimiziation of JAK2 potency while minimizing JAK3 activity
    McPherson, Andrew
    Cao, Jianguo
    Chow, Chun
    Fine, Richard
    Hood, John
    Kang, Xinshan
    Klebansky, Boris
    Lohse, Dan
    Mak, Chi Ching
    Noronha, Glenn
    Pathak, Ved P.
    Renick, Joel
    Soll, Richard
    Zeng, Binqi
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2007, 233 : 779 - 779
  • [2] Pyrrolo[1,2-f]triazines as JAK2 inhibitors: Achieving potency and selectivity for JAK2 over JAK3
    Harikrishnan, Lalgudi S.
    Kamau, Muthoni G.
    Wan, Honghe
    Inghrim, Jennifer A.
    Zimmermann, Kurt
    Sang, Xiaopeng
    Mastalerz, Harold A.
    Johnson, Walter L.
    Zhang, Guifen
    Lombardo, Louis J.
    Poss, Michael A.
    Trainor, George L.
    Tokarski, John S.
    Lorenzi, Matthew V.
    You, Dan
    Gottardis, Marco M.
    Baldwin, Kathy F.
    Lippy, Jonathan
    Nirschl, David S.
    Qiu, Ruhui
    Miller, Arthur V.
    Khan, Javed
    Sack, John S.
    Purandare, Ashok V.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (05) : 1425 - 1428
  • [3] Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor
    Alfonso Quintás-Cardama
    Taghi Manshouri
    Zeev Estrov
    David Harris
    Ying Zhang
    Amos Gaikwad
    Hagop M. Kantarjian
    Srdan Verstovsek
    Investigational New Drugs, 2011, 29 : 818 - 826
  • [4] Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor
    Quintas-Cardama, Alfonso
    Manshouri, Taghi
    Estrov, Zeev
    Harris, David
    Zhang, Ying
    Gaikwad, Amos
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 818 - 826
  • [5] Novel, Potent and Selective JAK2 Inhibitors.
    Radimerski, Thomas
    Baffert, Fabienne
    Regnier, Catherine H.
    De Pover, Alain
    Pissot, Carole
    Gerspacher, Marc
    Brueggen, Josef
    Tavares, Gisele
    Blasco, Francesca
    Ledieu, David
    Nolan, Lynda
    Ruetz, Stephan
    Chene, Patrick
    Erdmann, Dirk
    Drueckes, Peter
    Furet, Pascal
    Lang, Marc
    Trappe, Joerg
    Vangrevelinghe, Eric
    Wartmann, Markus
    Hofmann, Francesco
    BLOOD, 2009, 114 (22) : 1453 - 1453
  • [6] Development of novel JAK2 inhibitors and PROTACs as chemical probes for the investigation of JAK2 inhibition and degradation
    Humphrey, Briley A.
    li, Bao
    Ferreira, Renan B.
    Ranatunga, Sujeewa R.
    Rowsell, Tegan M.
    Sun, Luxin
    Lawrence, Harshani R.
    Schonbrunn, Ernst
    Reuther, Gary
    Lawrence, Nicholas J.
    CANCER RESEARCH, 2023, 83 (07)
  • [7] Inhibitors of JAK2 and JAK3: an update on the patent literature 2010-2012
    Dymock, Brian W.
    See, Cheng Shang
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2013, 23 (04) : 449 - 501
  • [8] Involvement of JAK1, JAK2, and JAK3 in Stimulation of Functional Activity of Mesenchymal Progenitor Cells by Fibroblast Growth Factor
    Zyuz'kov, G. N.
    Zhdanov, V. V.
    Udut, E. V.
    Miroshnichenko, L. A.
    Simanina, E. V.
    Polyakova, T. Yu.
    Stavrova, L. A.
    Udut, V. V.
    Minakova, M. Yu.
    Dygai, A. M.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2016, 162 (02) : 240 - 243
  • [9] Involvement of JAK1, JAK2, and JAK3 in Stimulation of Functional Activity of Mesenchymal Progenitor Cells by Fibroblast Growth Factor
    G. N. Zyuz’kov
    V. V. Zhdanov
    E. V. Udut
    L. A. Miroshnichenko
    E. V. Simanina
    T. Yu. Polyakova
    L. A. Stavrova
    V. V. Udut
    M. Yu. Minakova
    A. M. Dygai
    Bulletin of Experimental Biology and Medicine, 2016, 162 : 240 - 243
  • [10] Go6976 is a novel and potent inhibitor of JAK2 and JAK3 tyrosine kinases both in vitro and in cellular assays
    Grandage, VL
    Linch, DC
    Khwaja, A
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 : 6 - 6
12345